Hims & Hers Health (HIMS) FY Conference May 15, 2025 10:40 AM ET Speaker0 All right, let's get started. I'm Niels Law, Managing Director here at JPMorgan and very excited to be joined by Yemi Okupe, CFO of Hims and Hers. So Yemi, great to have you here with us for the first time. You've been busy. Two weeks ago, you announced your partnership with Novo Nordisk. Last week, you had strong earnings. You announced a new COO, announced a new CTO, and raised a billion dollar convert. So we're excited to have you ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Investor based in Geneva, Switzerland. Follow me on Twitter @GenevaInvestor for daily macro & investing nuggets. I write about macroeconomics, global trends, and what I believe are asymmetric investment opportunities in the market. I have a Master's degree in Business Management. I am currently bullish on PLTR, US equities, Bitcoin. Friend "Rex Investing" is also a contributor to Seeking Alpha. Check out our Podcast: ‘Stock Market Lube’, available on Spotify.All opinions and analysis on SA are exclusively m ...

Core Insights - Hims & Hers Health experienced a significant decline in stock price, dropping from $70 per share in February 2025 to a precarious position a few months later, indicating potential challenges within the telehealth sector [1]. Company Overview - Hims & Hers Health was previously considered a leading company in the telehealth industry, reflecting its strong market presence and investor interest during its peak [1]. Market Context - The telehealth sector has faced volatility, as evidenced by Hims & Hers Health's dramatic stock price fluctuations, which may suggest broader industry challenges or shifts in investor sentiment [1].

Core Insights - Hims & Hers has successfully upsized its convertible debt offering from $450 million to $1 billion, indicating strong investor confidence and financial backing for future growth [1] - The company is experiencing significant stock price appreciation in 2025, reflecting positive market sentiment and performance [1] - Future growth strategies for Hims & Hers include international expansion and increased integration of artificial intelligence in its operations [1]

My goal is to help you find the companies of tomorrow.I am a long-term growth investor in search of innovative companies that make the world a better place. My investment strategy revolves around finding what I call "divergent stocks" — disruptive companies that have strong fundamentals and long growth runways, but depressing prices.You can find me on YouTube as well:https://www.youtube.com/@riyadosofianAnalyst’s Disclosure: I/we have a beneficial long position in the shares of HIMS either through stock own ...

Following the company's first-quarter earnings report, shares of Hims & Hers Health (HIMS 5.21%) opened the following day considerably lower, only to sprint higher once trading began. This action is just one example of why the stock is a bit of a divisive name among investors. This can also be seen in its high short interest, which sits above 25%.The stock is up around 108% year to date (as of this writing), while at the same time it's down about 27% from the highs it set earlier this year. Let's take a clo ...

Hims & Hers Health (NYSE: HIMS ) has recently published their Q1 2025 earnings , which showed impressive growth metrics as well as ambitious guidance for 2030. When underlying the management's guidance, the company seems to beGerman Buy-Hold-Check investor. With a master's degree in engineering and management, I am able to understand, quantify, and interpret both the economics and (to some point) the technology of companies.Analyst’s Disclosure: I/we have a beneficial long position in the shares of HIMS eit ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...